新型喹诺酮类药物OPC - 17116、氧氟沙星及司帕沙星对肺炎衣原体的体外活性
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
作者信息
Roblin P M, Montalban G, Hammerschlag M R
机构信息
Department of Pediatrics, State University of New York Health Science Center at Brooklyn 11203.
出版信息
Antimicrob Agents Chemother. 1994 Jun;38(6):1402-3. doi: 10.1128/AAC.38.6.1402.
Abstract
The in vitro susceptibilities of 12 strains of Chlamydia pneumonia to a new quinolone, OPC-17116; ofloxacin; and sparfloxacin were determined. OPC-17116 was slightly less active than sparfloxacin but more active than ofloxacin, with a MIC for 90% of strains tested and a minimal chlamydiacidal concentration for 90% of strains tested of 0.5 micrograms/ml.
摘要
测定了12株肺炎衣原体对一种新型喹诺酮类药物OPC - 17116、氧氟沙星和司帕沙星的体外敏感性。OPC - 17116的活性略低于司帕沙星，但高于氧氟沙星，其对90%受试菌株的最低抑菌浓度（MIC）和对90%受试菌株的最低杀衣原体浓度为0.5微克/毫升。
相似文献
1
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1994 Jun;38(6):1402-3. doi: 10.1128/AAC.38.6.1402.
2
In vitro activities of five quinolones against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1992 Mar;36(3):682-3. doi: 10.1128/AAC.36.3.682.
3
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
4
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
Antimicrob Agents Chemother. 1997 Jun;41(6):1331-4. doi: 10.1128/AAC.41.6.1331.
5
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
6
In vitro activity of trovafloxacin against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
7
Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 1993 Oct;37(10):2244-6. doi: 10.1128/AAC.37.10.2244.
8
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
Antimicrob Agents Chemother. 1996 Apr;40(4):1048-9. doi: 10.1128/AAC.40.4.1048.
9
Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.
Antimicrob Agents Chemother. 1994 Aug;38(8):1757-62. doi: 10.1128/AAC.38.8.1757.
10
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
J Antimicrob Chemother. 1993 Apr;31(4):497-504. doi: 10.1093/jac/31.4.497.
引用本文的文献
1
In vitro and in vivo activities of sitafloxacin against Chlamydia spp.
Antimicrob Agents Chemother. 2001 Nov;45(11):3270-2. doi: 10.1128/AAC.45.11.3270-3272.2001.
2
Activity of quinolones against Chlamydia pneumoniae.
Drugs. 1999;58 Suppl 2:78-81. doi: 10.2165/00003495-199958002-00015.
3
Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection.
Infect Dis Obstet Gynecol. 1998;6(3):109-15. doi: 10.1002/(SICI)1098-0997(1998)6:3<109::AID-IDOG3>3.0.CO;2-S.
4
In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1998 Jun;42(6):1515-6. doi: 10.1128/AAC.42.6.1515.
5
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
6
In vitro activity of trovafloxacin against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
7
In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):696-8. doi: 10.1007/BF01691164.
8
Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections.
Drugs. 1995;49 Suppl 2:257-9. doi: 10.2165/00003495-199500492-00061.
9
Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1994 Sep;38(9):1873-8. doi: 10.1128/AAC.38.9.1873.
本文引用的文献
1
In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.
Antimicrob Agents Chemother. 1993 Apr;37(4):801-3. doi: 10.1128/AAC.37.4.801.
2
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
J Antimicrob Chemother. 1993 Apr;31(4):497-504. doi: 10.1093/jac/31.4.497.
3
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
4
In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.
Antimicrob Agents Chemother. 1988 Oct;32(10):1500-2. doi: 10.1128/AAC.32.10.1500.
5
Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.
Am J Med. 1990 Dec;89(6):722-4. doi: 10.1016/0002-9343(90)90212-v.
6
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.
J Infect Dis. 1990 Apr;161(4):618-25. doi: 10.1093/infdis/161.4.618.
7
Infection with Chlamydia pneumoniae in Brooklyn.
J Infect Dis. 1991 Apr;163(4):757-61. doi: 10.1093/infdis/163.4.757.
8
Persistent infection with Chlamydia pneumoniae following acute respiratory illness.
Clin Infect Dis. 1992 Jan;14(1):178-82. doi: 10.1093/clinids/14.1.178.
9
In vitro activities of five quinolones against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1992 Mar;36(3):682-3. doi: 10.1128/AAC.36.3.682.
10
In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.
Antimicrob Agents Chemother. 1992 Mar;36(3):573-9. doi: 10.1128/AAC.36.3.573.
Zotero 插件